



Present and Future of Hadrontherapy

Saverio Braccini

*Center for Research and Education in Fundamental Physics
LHEP – Laboratory for High Energy Physics
University of Bern, Switzerland*



- **Introduction**
 - **Fundamental research in physics and medical applications**
- **Conventional radiation therapy**
- **Hadrontherapy, the new frontier of cancer radiation therapy**
 - **Proton-therapy**
 - **Carbon ion therapy**
- **Some new ideas for the future of hadrontherapy**
- **Conclusions and outlook**

The starting point

- November 1895 : discovery of X rays



Wilhelm Conrad Röntgen



- December 1895 : first radiography
- First application of *photons* to medicine much before Einstein (1905) and the concept of light quanta!

The starting point

- 1896 : discovery of natural radioactivity





Henri Becquerel



Maria Skłodowska-Curie and Pierre Curie

From the thesis of Mme Curie – 1904

α , β , γ rays in a magnetic field



- 1908 : first attempts of radiation therapy in France
- The name “*curiethérapie*” is still used!

Picture: Dr. Chicotel, Musée de l'Assistance Publique, Paris

STOCKHOLM



1902

1912

Courtesy J.P. Jerard, MD, Nice (France)

- **Basic concept: Local control of the tumour!**


A big step forward...

...in high energy physics and in


- Medical diagnostics**
- Cancer radiation therapy**

is due to the development of three fundamental tools

- Particle accelerators**
- Particle detectors**
- Computers**




**M. S. Livingston and E. Lawrence
with the first cyclotron**



**Geiger-Müller counter built by
E. Fermi and his group in Rome**

The Lawrence brothers and interdisciplinary research



John H. Lawrence made the first clinical therapeutic application of an artificial radionuclide when he used phosphorus-32 to treat leukemia. (1936)




- John Lawrence, brother of Ernest, was a medical doctor
- They were both working in Berkeley
- First use of artificially produced isotopes for medical diagnostics
- First irradiations of salivary gland tumours with neutron beams

An interdisciplinary environment helps innovation!

The electron linac

Sigurd Varian

William W. Hansen




Russell Varian

1939

Invention of the klystron

The electron linac is used today in hospital based conventional radiation therapy facilities



~ 1 m

1947
first linac for electrons
4.5 MeV and 3 GHz

Accelerators running in the world

CATEGORY OF ACCELERATORS	NUMBER IN USE (*)
High Energy acc. (E >1GeV)	~120
<u>Synchrotron radiation sources</u>	<u>>100</u>
<u>Medical radioisotope production</u>	<u>~200</u>
<u>Radiotherapy accelerators</u>	<u>> 7500</u>
Research acc. included biomedical research	~1000
Acc. for industrial processing and research	~1500
Ion implanters, surface modification	>7000
TOTAL	<u>> 17500</u>

9000

(*) W. Maciszewski and W. Scharf: Int. J. of Radiation Oncology, 2004


- About half are used for bio-medical applications!

Diagnostics and imaging are essential!

Computer Tomography (CT)




Abdomen




- Measurement of the electron density
- Information on the morphology

Radiotherapy with X-rays



- **Electron linacs to produce gamma rays (called X-rays by medical doctors)**
- **20'000 patients/year every 10 million inhabitants**

How does it work?




- TC scan data are used to


- design the volume to be irradiated
- choose the radiation fields
- calculate the doses to the target and to healthy tissues

- The dose is given in about 30-40 fractions of about 2 Gray

The basic problem of X ray therapy



An example of dose distribution with X rays




9 different photon beams

Use of many crossed beams to irradiate the target and spare at best the healthy tissues

**The limit is due to the dose given to the healthy tissues!
Especially to the organs at risk (OAR)**


Intensity Modulated Radiation Therapy (IMRT)



Multi leaf collimator which moves during irradiation

- It is possible to obtain concave dose volumes
- Time consuming (used for selected cases)



A step forward towards dose conformation



Intensity Modulated Radiation Therapy (IMRT)


Let's go back to physics...

Fundamental physics
Particle identification



Medical applications
Cancer hadrontherapy


Single beam comparison




Protons and ions are more precise than X-rays

Tumour between the eyes


9 X ray beams



1 proton beam




The basic principles of hadrontherapy



- Bragg peak
 - Better conformity of the dose to the target → healthy tissue sparing
- Hadrons are charged
 - Beam scanning for dose distribution
- Heavy ions
 - Higher biological effectiveness

Why ions have a large biological effectiveness?



The first idea – Bob Wilson, 1946




- Bob Wilson was student of Lawrence in Berkley
- Study of the shielding for the new cyclotron
- Interdisciplinary environment = new ideas!
- Use of protons and charged hadrons to better distribute the dose of radiation in cancer therapy

R.R. Wilson, "Radiological Use of Fast Protons", *Radiology*, 47 (1946) 487

The beginning of hadrontherapy 1954 at Berkeley



- 1948- Biology experiments using protons
- 1954- Human exposure to accelerated protons and alphas
- 1956 - 1986: Clinical Trials– 1500 patients treated




Cornelius A. Tobias

C.A. Tobias, J.H. Lawrence et al., Cancer Research 18 (1958) 121

Today there are two main kind of treatments

● Treatment of eye-melanoma



- Shallow tumour
- About 65 MeV of energy are needed
- Relatively small cyclotrons
- Very high local control
- Many centres in operation (ex. Centre Antoine Lacassagne in Nice)



● Treatment of deep seated tumours

- Energies up to about 210 MeV are needed
- Much larger infrastructure

What do we need to treat deep seated tumours?



Fixed beam



Gantry




Accelerator

General scheme of a proton-therapy centre. The example reported here is based on the system commercialized by the company IBA (Belgium).

What does a patient see of all that?




Dose distribution (present): passive spreading



‘Double scattering’


These are the systems uses today in clinical practice!




‘Layer stacking’

Dose distribution (future): raster scanning

Longitudinal plane



Transverse plane



New technique developed and applied for treatments at GSI

The Gantry1 at PSI

SAMBA

Strip Accurate Monitor for Beam Applications


Measurement of a spot




T direction (table)

U direction (magnet)


Dose distribution (future): spot scanning




Single 'spot'



Lateral scanning with magnet: 2 ms/step





Depth scanning



Third scanning by a bending magnet and movable bed



New technique developed and applied for treatments at PSI

Organ motion (present): respiratory gating




- The beam reaches the patient only when the “gate” is ON
- Synchrotrons: synchronization of the respiration of the patient with the cycle of the accelerator
- Technique already in use in Japan (Tsukuba)


Moving organs (future): organ tracking



static



moving,
non-compensated



moving,
compensated

Sven O. Grözinger, GSI Darmstadt

Number of potential patients

X-ray therapy every 10 million inhabitants: 20'000 pts/year

Protontherapy

14.5% of X-ray patients = 2'900 pts/year

Therapy with Carbon ions for radio-resistant tumours

3% of X-ray patients = 600 pts/year

Every 50 M inhabitants

- Proton-therapy
4-5 centres**
- Carbon ion therapy
1 centre**

TOTAL about 3'500 pts/year
every 10 M

Results of clinical studies conducted in
Italy, France, Germany, Austria and Sweden

The treated sites

Eye and Orbit

- Choroidal Melanoma
- Retinoblastoma
- Choroidal Metastases
- Orbital Rhabdomyosarcoma
- Lacrimal Gland Carcinoma
- Choroidal Hemangiomas

Head and Neck Tumors

- Locally Advanced Oropharynx
- Locally Advanced Nasopharynx
- Soft Tissue Sarcoma
Recurrent or Unresectable
- Misc. Unresectable or Recurrent Carcinomas

Chest

- Non Small Cell Lung Carcinoma
Early Stage—Medically Inoperable
- Paraspinal Tumors
Soft Tissue Sarcomas, Low Grade Chondrosarcomas, Chordomas

Abdomen

- Paraspinal Tumors
- Soft Tissue
Sarcomas,
Low Grade
Chondrosarcomas,
Chordomas

Pelvis

- Early Stage Prostate
- Locally Advanced Prostate
- Locally Advanced Ovary
- Sacral Chordoma
- Recurrent or Unresectable Rectal Carcinoma
- Recurrent or Unresectable Pelvic Masses

Central Nervous System

- Adult Low Grade Gliomas
- Pediatric Gliomas
- Acoustic Neuroma
Recurrent or Unresectable
- Pituitary Adenoma
Recurrent or Unresectable
- Meningioma
Recurrent or Unresectable
- Craniopharyngioma
- Chordomas and
Low Grade Chondrosarcoma
Clivus and Cervical Spine
- Brain Metastases
- Optic Glioma
- Arteriovenous Malformations

Up to present

- **Proton-therapy:**
~ 55 000 patients

- **Carbon ion therapy:**
~ 2 200 patients



Present and “near” future of hadrontherapy

- **Proton-therapy is “booming”!** *(for information see PTCOG, ptcog.web.psi.ch)*
 - **Laboratory based centres: Orsay, PSI, INFN-Catania, ...**
 - **Hospital based centres: 3 in USA, 4 in Japan and many under construction (USA, Japan, Germany, China, Korea, Italy, ...)**
 - **Companies offer “turn-key” centres**


- **Carbon ion therapy**
 - **2 hospital based centres in Japan**
 - **Pilot project at GSI**
 - **2 hospital based centres under construction: HIT in Germany and CNAO in Italy**
 - **2 projects (almost) approved (ETOILE in France and Med-Austron in Austria)**
 - **European network ENLIGHT**

The Loma Linda University Medical Center (USA)


- First hospital-based proton-therapy centre, built in 1993
- ~160/sessions a day
- ~1000 patients/year




PROSCAN project at PSI



- New SC 250 MeV proton cyclotron – Installed
- New proton gantry for advanced scanning



Centre de protonthérapie de l'Institut Curie in Orsay




- Active from 1991
- 3766 patients treated (Dec-06)
- Extension (New cyclotron + Gantry by the Belgian company IBA)
- 650 patients par an à partir de 2009


Carbon ion therapy in Europe

1998 - GSI pilot project (G. Kraft)



200 patients treated
with carbon ions




PET on-beam



Measurement of the "real" 3D dose distribution given to the patient




HIT – University of Heidelberg



Heavy-ion Gantry
Weight: 600 t
25 m long
13 m diameter
Deformation < 0.5 mm

Carbon ion gantry
MAN technology




December 2006

- **Hospital based centre**
- **Project started in 2001**
- **First patient treatment foreseen in 2008**
- **First C-ion gantry**

The TERA Foundation

- Not-for-profit foundation created in 1992 by Ugo Amaldi and recognized by the Italian Ministry of Health in 1994
- Research in the field of particle accelerators and detectors for hadron-therapy

- First goal: the Italian National Centre (CNAO) now under construction in Pavia





- Collaborations with many research institutes and universities
 - in particular CERN, INFN, PSI, GSI, JRC, Universities of Milan, Turin and Piemonte Orientale

CNAO – Presented at the CERN Open Day April 2008

fondazione **CNAO**

Centro Nazionale di Adroterapia Oncologica
under construction in Pavia (Italy)



CNAO
Centro Nazionale di
Adroterapia Oncologica
Pavia


The challenges for the future of hadrontherapy

- Reduce costs, size and complexity
- Improve the quality of the treatment



1. Innovative (possibly compact) accelerators
2. Innovative compact gantries (especially for ions)
3. Techniques for dose distribution (especially to treat moving organs)
4. Synergies with advanced medical imaging
5. Optimization of the available medical resources

A SC cyclotron for carbon ion therapy



- Superconducting isochronous cyclotron, accelerating $Q/M = 1/2$ ions to 400 MeV/U (H²⁺, Alphas, Li^{6 3+}, B^{10 5+}, C^{12 6+}, N^{14 7+}, O^{16 8+}, Ne^{20 10+})

- Diameter 6.3 meters


- Design by IBA (Belgium)

- The first prototype will be realized in Caen by the Archade consortium



Advanced medical imaging: PET and PET-CT


- **FDG with ^{18}F is the most used drug (half life 110 minutes)**
- **Measurement of the density of ^{18}F through back-to-back gamma detection**
- **Information on metabolism**




Protons
~15-20 MeV, ~50 μA

Cyclotron


Gamma ray detectors
(Ex. BGO crystals)




PET tomograph




PET image



CT-PET



PET can help for planning in radiation therapy



Radio labeled tag	Molecular structure	Physiological parameter	Example of clinical use
¹⁸ F FDG	<chem>O[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O18F</chem>	Glucose utilization	Possible malignancy
¹⁸ F FLT	<chem>CC1=NC(=O)N(C[C@H]2O[C@@H](O)[C@H](O)[C@@H]2O18F)C1=O</chem>	Cell proliferation	Possible malignancy
¹⁸ F MISO	<chem>CC(O)C1=CN=C(C=C1)[N+](=O)[O-]18F</chem>	Cell proliferation	Determining radiation exposure
¹⁸ F FDDNP	<chem>CC(C#N)=C(C#N)C1=CC=C(C=C1)N(C)CC18F</chem>	Amyloid plaque binding agent	Alzheimer's disease marker

R. Nutt et al., **CLINICAL PHARMACOLOGY & THERAPEUTICS**,


Vol. 81 Num. 6, Pag. 792, June 2007

IDRA: a project promoted by the TERA Foundation

IDRA

Institute for **D**iagnostics and **RA**diotherapy

30 MeV cyclotron




Linear accelerator
LIBO

Gantries and fixed beam lines
for treatment and research



The challenge of medical sciences

Three fundamental questions to detect and cure the disease:



Some examples :

- Non-invasive screening (molecular markers, imaging, ...)
- High precision diagnostics (MRI, TC, PET, SPECT, ...)
- High precision non-invasive therapy (hadrontherapy, ...)


Conclusions and Outlook

- **Since the beginning of particle physics, more than one-hundred years go...**

Particle physics offers medicine and biology very powerful tools and techniques to study, detect and attack the disease

To fully exploit this large potentiality, all these sciences must work together!

Work is in progress...



**Physics is beautiful...
...and useful !**